Estrella Immunopharma Stock (NASDAQ: ESLAW)

Latest news for Estrella Immunopharma (NASDAQ:ESLAW) Stock

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Inc

Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares are trading higher. The company on Monday announced that its cannabis cultivation facility in Germany received the first new cannabis cultivation license issued under <a href="https://www.benzinga.com/pressreleases/24/07/g39879382/tilray-receives-first-new-cannabis-cultivation-license-in-germany-under-new-regulations">Germany&#8217;s new Cannabis Act</a>.
What To Know: Tilray said Aphria RX GmbH received&nbsp;the first new cannabis cultivation license issued under MedCanG. The license will allow Tilray&#8217;s German facility to cultivate and manufacture a broad commercial range of medical cannabis.
&#8220;We are thrilled to receive this license as it will provide greater access to some of the highest quality medical cannabis produced in Germany and enable us to expand the range of treatment options available to patients,&#8221; said Denise Faltischek, chief strategy officer and head of international for Tilray. 
&#8220;We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care.&#8221;
Tilray said it strongly believes these developments will have a positive impact on the health and well-being of many patients in Germany.&nbsp;The company noted that the introduction of the German cannabis bill has led to a significant increase in the number of patients and prescribers for medical cannabis.
Tilray is due to report <a href="https://www.benzinga.com/calendars/earnings">earnings for the fourth quarter</a> after the market close on July 29. 
See Also:<a href="https://www.benzinga.com/markets/cannabis/24/07/39874209/joe-biden-drops-out-what-would-happen-with-cannabis-legalization-under-kamala-harris-or-donald-t"> Joe Biden Drops Out: What Would Happen With Cannabis Legalization Under Kamala Harris Or Donald Trump?</a>
<h2 class="wp-block-heading">How To Buy TLRY Stock</h2>
By now you're likely curious about how to participate in the market for Tilray &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Tilray , which is trading at $1.79 as of publishing time, $100 would buy you 55.87 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
TLRY Price Action: <a href="https://www.benzinga.com/quote/TLRY">Tilray shares</a> were up 3.35% at $1.85 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Anan Kaewkhammul/Shutterstock.

Cannabis

News

Global

Movers

TLRY

What's Going On With Tilray Brands Stock Monday?

The number of states where recreational weed is legal is growing each year. Top-selling states like California and Michigan have reported $2.1 billion and $1.6 billion, respectively, in recreational cannabis sales for the first half of 2024, as <a href="https://www.greenmarketreport.com/california-leads-the-industry-in-cannabis-sales-at-six-month-mark/">reported</a> by Green Market Report's Debra Borchardt.
California cannabis supremacy can't be argued even though many experts have insisted the state's <a href="https://www.benzinga.com/markets/cannabis/24/06/39195663/legal-california-cannabis-market-on-the-verge-of-collapse-while-illegal-growers-thrive-destroyin">marijuana market is &#8220;on the verge of collapse.&#8221; </a>On the other hand, the Golden State is home to the California State Fair at Cal Expo which just recently, for the first time in its 170-year history, allowed on-site cannabis <a href="https://www.benzinga.com/markets/cannabis/24/07/39782466/californias-first-cannabis-friendly-state-fair-with-on-site-sales-and-consumption">sales and consumption.</a>
Moreover, exciting news that Snoop Dogg is set to open his first licensed cannabis store, S.W.E.D., near Los Angeles International Airport (LAX) made headlines last week. The new shop will no doubt be a cultural hub in Los Angeles, offering top-shelf <a href="https://www.benzinga.com/markets/cannabis/24/07/39733952/snoop-dogg-to-open-weed-stores-in-la-amsterdam-named-after-iconic-smoke-weed-every-day-motto">premium products and services.</a>
<h3 class="wp-block-heading">Michigan's Market Is Thriving</h3>
Meanwhile, Michigan&#8217;s cannabis market is indisputably thriving marked by <a href="https://www.benzinga.com/markets/cannabis/24/07/39758729/cannabis-concentrates-brands-with-strong-growth-acquisition-targets-amid-industry-consolidation">high-growth brands</a> and a robust market structure, as highlighted by Benzinga's <a href="https://www.benzinga.com/author/nicol-s-jose-rodriguez">Nicolás Jose Rodriguez</a> in a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39828818/michigans-cannabis-market-hits-837m-record-whats-driving-the-boom-in-the-midwest">recap</a> of a report by Beacon Securities.
That report praised the performance of notable public companies in Michigan, including Ascend Wellness Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#CSE">AAWH</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTCQX">AAWH</a>), Grown Rogue International Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#CSE">GRIN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>), TerrAscend Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTC">TSNDF</a>) and Red White &amp; Bloom Brands Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/RWB#CSE">RWB</a>) while a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38282615/cannabis-brands-leading-market-expansion-in-east-midwest-a-look-at-prices-and-trend">cannabis sector analysis</a> by Pablo Zuanic of Zuanic &amp; Associates underscored that the state&#8217;s market is highly fragmented, with Cresco&#8217;s High Supply and Ascend Wellness&#8217;s Ozone leading various segments, including the flower category.
Nevertheless, new data from <a href="https://www.benzinga.com/markets/cannabis/24/03/37521749/unpacking-the-58b-cannabis-market-boom-bdsa-forecasts-for-2028">cannabis analytics</a> firm BDSA revealed Michigan has emerged as the top seller of legal cannabis in the U.S., surpassing the Golden State in unit sales. Michigan sold 22 million cannabis products in March, compared to 21.3 million units sold in California over the same month. That milestone was the first time another state has outsold <a href="https://www.benzinga.com/markets/cannabis/24/06/39207863/michigan-beats-california-in-legal-cannabis-sales-why-is-golden-states-weed-industry-losing-its-">California in legal cannabis products.</a> Another milestone is a per capita sales of 21+ population of $233.97 in Michigan compared to $74.90 in California.
Yet marijuana sales in Michigan on <a href="https://www.benzinga.com/markets/cannabis/24/07/39820832/michigan-top-seller-of-legal-cannabis-in-us-reports-flat-sales-in-june-colorados-marijuana-downt">a monthly basis</a> have been flat over the past couple of months with June figures of $278.8 million, representing a 6.9% year-over-year growth or &#8220;the slowest annual growth in over two years,&#8221; <a href="https://www.newcannabisventures.com/michigan-cannabis-sales-slow/">according</a> to New Cannabis Venture&#8217;s Alan Brochstein.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31357863/shop-legal-weed-at-michigans-top-rated-cannabis-dispensaries-here-are-the-shops-made-the-list">Shop Legal Weed At Michigan&#8217;s Top Rated Cannabis Dispensaries, Here Are The Shops Made The List</a>
<h3 class="wp-block-heading">Remaining Top 3</h3>
As Green Market Report's compilation of sales data showed, Illinois with its roughly $851 million figure in legal marijuana sales for the first half of 2024 came third. Combined with medical sales, the total cannabis sales figure reached $1 billion as <a href="https://www.benzinga.com/markets/cannabis/24/07/39731191/illinois-2024-cannabis-sales-reach-1b-milestone-faster-than-expected-are-out-of-state-consumers-">recently reported by Gov. JB Pritzker‘s office.</a>
Illinois will welcome a slew of top cannabis entrepreneurs, experts and executives at this fall&#8217;s Benzinga Cannabis Capital Conference in Chicago on Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
Massachusetts and Missouri followed with $795 million and $709 million, respectively, in recreational cannabis sales reported in the first six months of 2024.
Massachusetts Cannabis Control Commission's (CCC) recent data showed that combined medical and cannabis sales dipped <a href="https://www.benzinga.com/markets/cannabis/24/07/39670141/massachusetts-cannabis-sales-decline-slightly-in-june-despite-annual-quarterly-growth">slightly in June</a>, marking a 2% month-over-month decrease from $155 million in May to $152 million. Some of the major players doing business in the nascent market are AYR Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>), The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTCQX">CBSTF</a>) (FSE: 3LP), Curaleaf International (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ) and Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/04/38261253/missouris-2b-marijuana-market-hits-record-sales-in-march-eyes-future-growth-with-microbusiness-l">Missouri&#8217;s $2B Marijuana Market Hits Record Sales In March, Eyes Future Growth With Microbusiness Licenses </a></li>
</ul>

Retail Sales

AAWH

AYRWF

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CRLBF

CSE:AAWH

CSE:CL

CSE:GRIN

CSE:RWB

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

GTBIF

TSNDF

Cannabis Is Flying Off The Shelves In These Five States, Earning Billions For Marijuana Companies

Wells Fargo analyst Hanwen Chang maintains Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) with a Equal-Weight and lowers the price target from $54 to $50.

Price Target

Analyst Ratings

VTLE

Wells Fargo Maintains Equal-Weight on Vital Energy, Lowers Price Target to $50

In a surprising turn of events, Chinese social media users and former President Donald Trump have come to a shared conclusion: Vice President Kamala Harris has a slim chance of winning the upcoming November elections.
What Happened: Chinese social media platform Weibo is buzzing with discussions suggesting that Trump&#8217;s victory is a foregone conclusion. This sentiment has been fueled by a failed assassination attempt on Trump, Business Insider <a href="https://www.businessinsider.in/politics/world/news/china-finally-agrees-with-trump-on-something-they-both-think-kamala-harris-cant-win/articleshow/111918971.cms">reported</a> on Monday.
President Joe Biden&#8216;s decision to step down from the election race has gone viral in China, with online consensus leaning towards Trump&#8217;s campaign rhetoric. Initial reactions from Chinese commentators have dismissed Harris, endorsed by Biden as the Democratic nomination, as having an even lower chance of winning the White House than Biden himself.
Trump, now the official Republican nominee, echoed this sentiment on Sunday, stating that Harris would be &#8220;easier to beat than Joe Biden would have been.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/07/39877062/nvidia-reportedly-developing-a-new-version-of-its-flagship-ai-chip-for-chinese-market-amid-us-export?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia Reportedly Developing A New Version Of Its Flagship AI Chip For Chinese Market Amid US Export Rest</a>
While China&#8217;s heavily moderated social media is not a true indicator of its foreign policy, these discussions provide insight into the rhetoric the authorities allow to thrive. 
&#8220;Trump has basically secured the presidency, there&#8217;s no need for others to continue the act. It&#8217;s awkward and not even entertaining,&#8221; wrote one blogger based in Gansu.
&#8220;The Democratic Party&#8217;s chaotic replacement of generals is like the medicine of Wu Dalang,&#8221;&nbsp;another blogger wrote, referring to a famous Chinese tale of a man who survived poisoning but was still suffocated to death by his wife. 
&#8220;You will die whether you take it or not.&#8221;
Why It Matters: Despite the predictions from Trump and China, a FiveThirtyEight round-up of the latest polls shows that Harris&#8217; <a href="https://fivethirtyeight.com/">performance with voters </a>differs from Biden&#8217;s by only a small margin — typically by one or two percentage points at most. At times, she fares better than the president.
However, the relationship between China and the U.S. could <a href="https://www.benzinga.com/news/24/05/39036025/second-trump-term-could-lead-to-confrontational-relationship-between-china-us-says-expert-likely-exp">face new challenges </a>if Trump wins the upcoming U.S. presidential election, according to a Chinese expert. Jia Qingguo, a professor at Peking University, warned of increased confrontations if Trump is re-elected.
Furthermore, the U.S. Ambassador to China, Nicholas Burns, has leveled serious accusations against Beijing, stating that it is actively <a href="https://www.benzinga.com/news/24/06/39481245/us-envoy-slams-china-for-undermining-diplomatic-relations-taking-dramatic-steps-to-make-it-impossibl">sabotaging diplomatic relations </a>between the two nations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39858529/amid-russia-china-tensions-us-bolsters-defenses-with-new-satellite-jammers-that-can-responsibly-coun?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amid Russia-China Tensions, US Bolsters Defenses With New Satellite Jammers That Can &#8216;Responsibly Counter</a></li>
</ul>
Photo by Sheila Fitzgerald on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

General

Chinese Social Media Users Think Kamala Harris Can't Win Against Trump: 'It's Awkward And Not Even Entertaining'

Data from prediction market platform Polymarket indicates that bettors think former First Lady Michelle Obama may have a chance at becoming the Democratic nominee for <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39880291/president-bidens-exit-followed-nearly-80m-in-wagers-on-crypto-prediction-market-polymarket">the Presidential election</a>.
The <a href="https://polymarket.com/event/democratic-nominee-2024?tid=1721653988893">market</a>, which has attracted over $214 million in bets, gives Michelle Obama a 11% chance of replacing President Joe Biden as the nominee, making her the second favorite after Vice President Kamala Harris. $24 million have been traded on the prospects of the former First Lady alone.
The betting trend shows Obama&#8217;s chances more than tripling in the last 24 hours alone, from 3% to over 10%.
This uptick could be interpreted as a response to recent political developments, including President Joe Biden&#8216;s unexpected withdrawal from the race and his endorsement of Vice President Kamala Harris <a href="https://www.benzinga.com/news/24/07/39875181/trump-wants-republicans-reimbursed-after-biden-quits-we-have-to-start-all-over-again">as the Democratic nominee.</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39880421/bitcoin-dominates-ethereum-rebounds-heres-how-much-crypto-funds-raked-in-last-week#google_vignette">Bitcoin Dominates, Ethereum Rebounds: Here&#8217;s How Much Crypto Funds Raked In Last Week</a>
Entrepreneur and investor Balaji S. Srinivasan <a href="https://x.com/balajis/status/1815122771019731401">said</a>, &#8220;Obama is not endorsing Kamala. He&#8217;s calling for an open convention. Michelle Obama may be his nominee.&#8221; This statement, while not reflected in the current betting odds, has added fuel to ongoing discussions about potential shake-ups in the Democratic field.
Speculations about Michelle Obama have abounded, despite the former First Lady being on record <a href="https://www.axios.com/2024/06/27/michelle-obama-private-frustration-bidens-2024-election">saying</a> &#8220;you would be crazy to go into politics.&#8221;
Anastasija Plotnikova, CEO of Fideum told Benzinga that Donald Trump is currently favored to win the upcoming Presidential election, with 72% of bets in his favor in a separate market. That market has seen over $260 million in bets, dwarfing the volume in the Michelle Obama market.
What&#8217;s Next: For those seeking to delve deeper into the future of digital assets and their potential impact on various sectors, including politics, the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets </a>event on Nov. 19 promises to offer valuable insights.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39867522/trump-campaign-eyes-crypto-voters-what-vp-jd-vances-nomination-means-for-bitcoin">Trump Campaign Eyes Crypto Voters: What VP JD Vance&#8217;s Nomination Means For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Michelle Obama For Democratic Nominee? Crypto Bettors Think Her Odds Have Just Tripled

Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported worse-than-expected second-quarter <a href="https://www.benzinga.com/news/earnings/24/07/39858954/halliburtons-q2-revenue-miss-highlights-challenges-in-us-market-despite-international-gains">revenue results on Friday</a>.
Halliburton reported second-quarter 2024 revenue of $5.833 billion, missing the consensus of $5.949 billion. EPS of 80 cents was in line with the consensus, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Completion and Production revenue was $3.4 billion, flat Q/Q, while Drilling and Evaluation revenue came in at $2.4 billion, flat Q/Q.
International revenue was $3.4 billion, an increase of 3% Q/Q, with revenue from Latin America flat Q/Q, Europe/Africa +4% Q/Q, and Middle East/Asia +5% Q/Q.
Jeff Miller, Chairman, President, and CEO, said, "In our international markets we see strong demand for Halliburton's services, high activity levels, and equipment tightness across all major basins."
Halliburton shares fell 5.6% to close at $34.40 on Friday.
These analysts made changes to their price targets on Halliburton following the announcement.
<ul>
<li>Susquehanna analyst Charles Minervino maintained Halliburton with a Positive rating, while lowering the price target from $49 to $46.</li>
<li>Piper Sandler analyst Luke Lemoine maintained the stock with an Overweight rating and cut the price target from $46 to $40.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

Earnings

Markets

Trading Ideas

Halliburton Analysts Lower Their Forecasts After Q3 Results

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) is <a href="https://www.benzinga.com/markets/equities/24/07/39874391/tesla-alphabet-gm-ford-lead-earnings-parade-this-week-as-market-struggles-to-sustain-the-summer-">scheduled to release its second-quarter results</a> after the market close on Tuesday, and ahead of the release, a bullish analyst reiterated his positive stance. The Google parent is the first AI stalwart to report this earnings season and therefore, all eyes will be riveted on the report.
Analysts, on average, expect the company to report earnings of $1.85 per share compared to the year-ago&#8217;s $1.44, and revenue of $84.20 billion versus last year&#8217;s $74.60 billion.
The Alphabet Analyst: Wedbush analyst Scott Devitt reiterated an Outperform rating and $205 price target for the stock. 
The Alphabet Thesis: &#8220;The setup remains positive heading into 2Q results,&#8221; said Devitt, citing findings from the firm&#8217;s ad survey and agency commentary that pointed to continued strength for Google Search. The analyst said he raised his Google Search revenue growth estimate from 12% to 12.8% to $47.75 billion. Sequentially search revenue is now expected to see a more modest sequential deceleration in growth, he added.
The survey results have increased conviction in spending intent for the full year, the Wedbush analyst said.
See Also:<a href="https://www.benzinga.com/money/best-communication-services-stocks"> Best Communication Services Stocks</a>
Devitt expects operating income to exceed consensus estimates by about 2%. &#8220;With cost controls still in place, we expect continued operating margin expansion in 2Q,&#8221; he said, adding that operating margin will likely come in at 31.7% versus the 31.1% consensus estimate.
The analyst said the chances of seeing a negative surprise related to spending are relatively low in the second quarter as the increased capital intensity is better understood and estimates for depreciation &amp; amortization and capex have risen materially following guidance last quarter. 
Devitt said he would focus on the following:
<ul>
<li>operating expense and CapEx growth related to AI investments</li>
<li> 2H advertising growth as comps become more challenging</li>
<li>ongoing monetization of AI services within the cloud unit</li>
</ul>
Alphabet Price Action: Alphabet&#8217;s Class A shares listed on the Nasdaq rose 1.43% to $180.20 in premarket trading on Monday, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a> The stock is up over 27% for the year-to-date period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39820669/google-parent-alphabets-q2-expected-to-shine-with-ai-youtube-shorts-cloud-strength-analyst">Google Parent Alphabet&#8217;s Q2 Expected To Shine With AI, YouTube Shorts, Cloud Strength: Analyst</a></li>
<li></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Previews

Reiteration

Tech

GOOG

GOOGL

Alphabet Set To Report Strong Q2 Results With Increased Search Revenue: Analyst Bullish On Google Parent Flags 3 Things That Will Be On His Radar

Wells Fargo analyst Zachary Fadem maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Overweight and raises the price target from $285 to $295.

TSCO

Wells Fargo Maintains Overweight on Tractor Supply, Raises Price Target to $295

Wells Fargo analyst Ike Boruchow maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Overweight and raises the price target from $275 to $300.

BURL

Wells Fargo Maintains Overweight on Burlington Stores, Raises Price Target to $300

<ul>
<li>NVDA</li>
<li>TSLA</li>
<li>CRWD</li>
<li>WAY</li>
<li>DJT</li>
<li>TSM</li>
<li>QQQ</li>
<li>AMD</li>
<li>LOT</li>
<li>AI</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CRWD

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 22 2024 (Via Swaggy Stocks)

WIIM

Shares of Nvidia are trading higher following a report suggesting the company is preparing a version of its AI chips for the Chinese market. Additionally, Piper Sandler maintained an Overweight rating and raised its price target from $120 to $140.

Monday, Hepion Pharmaceuticals Inc (NASDAQ:&nbsp;HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39880821/pharma-two-b-announces-plans-to-go-public-via-merger-with-hepion-pharmaceuticals-inc-and-concurren" rel="noreferrer noopener">development for Parkinson&#8217;s Disease</a>.
The merger is valued at an estimated pro-forma implied equity value of approximately $58.5 million.
Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B.
The combined company will continue to operate under the &#8220;Pharma Two B&#8221; name. Pharma Two B has agreed to file a registration statement with the SEC to register the ordinary shares proposed to be issued to Hepion&#8217;s equity holders in the acquisition. It will also apply to list its ordinary shares on Nasdaq under the ticker symbol &#8220;PHTB.&#8221;
&#8220;P2B001 offers a novel, easy-to-use therapeutic approach, that is designed to address the unmet need for an effective, safe, once-daily, no titration required treatment with a lower incidence of excessive daytime sleepiness—a common side effect of currently available dopamine agonist treatments in Parkinson&#8217;s disease patients&#8221; said Dan Teleman, Chief Executive Officer of Pharma Two B.
&#8220;Our company is in a stage that we believe meets the public market and investors&#8217; expectations. We are excited about Pharma Two B&#8217;s next growth phase, moving P2B001 towards an NDA submission targeted for the first half of 2026 and making this potential treatment available to patients,&#8221; he continued.
Hepion has also announced a private placement of $2.9 million non-convertible senior notes to qualified institutional investors.
Pharma Two B has entered into a securities purchase agreement for an $11.5 million private placement of ordinary shares and accompanying Series A warrants and Series B warrants.
In April, Hepion Pharmaceuticals began wind-down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38342739/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial" rel="noreferrer noopener">announced in December 2023</a>.
Price Action: HEPA stock is up 1.96% at $1.04 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39881151/johnson-johnson-faces-legal-hurdle-in-talc-lawsuit-battle" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Faces Legal Hurdle In Talc Lawsuit Battle</a>.</li>
</ul>

Biotech

Health Care

HEPA

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li>Goldman Sachs cut the price target for Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from $38 to $37.5. Wedbush analyst Nick Setyan downgraded the stock from Outperform to Neutral. Chuy&#8217;s shares fell 0.7% to close at $37.08 on Friday. <a href="https://www.benzinga.com/quote/CHUY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities decreased Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) price target from $55 to $53. Truist Securities analyst Brandon King downgraded the stock from Buy to Hold. Comerica shares fell 10.5% to close at $50.42 on Friday. <a href="https://www.benzinga.com/quote/CMA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities boosted the price target for Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) from $6 to $8. B. Riley Securities analyst Mike Crawford downgraded the stock from Buy to Neutral. Redwire shares fell 0.9% to close at $6.98 on Friday. <a href="https://www.benzinga.com/quote/RDW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) price target from $95 to $115. Stifel analyst Mark Astrachan upgraded the stock from Hold to Buy. International Flavors shares fell 1% to close at $95.67 on Friday. <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $81 to $92. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. Henry Schein shares fell 0.5% to close at $70.34 on Friday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) price target from $75 to $70. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. Alaska Air shares gained 1.8% to close at $37.93 on Friday. <a href="https://www.benzinga.com/quote/ALK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $500. Deutsche Bank analyst Lauren Silberman maintained a Buy rating. Domino&#8217;s shares fell 1.2% to close at $404.17 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) price target from $167 to $194. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Abercrombie &amp; Fitch shares gained 1% to close at $158.51 on Friday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39876945/s-p-500-logs-worst-weekly-decline-since-april-investor-optimism-falls-further">S&amp;P 500 Logs Worst Weekly Decline Since April; Investor Optimism Falls Further</a></li>
</ul>

CHUY

HSIC

ITCI

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Piper Sandler analyst Scott Siefers maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Underweight and raises the price target from $11.5 to $13.5.

HBAN

Piper Sandler Maintains Underweight on Huntington Bancshares, Raises Price Target to $13.5

Barclays analyst Jared Shaw maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Overweight and raises the price target from $86 to $92.

Barclays Maintains Overweight on Western Alliance, Raises Price Target to $92

Barclays analyst Eric Beaumont maintains WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Underweight and raises the price target from $78 to $80.

Barclays Maintains Underweight on WEC Energy Group, Raises Price Target to $80

Piper Sandler analyst Luke Lemoine maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Overweight and lowers the price target from $46 to $40.

Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $40

By&nbsp;Lance Roberts
Over the last few years, a handful of&nbsp;&ldquo;Mega-Capitalization&rdquo;&nbsp;(mega-market capitalization)&nbsp;stocks have dominated market returns. The question is whether that dominance will continue and if the same companies remain the leaders. It is an interesting question. The number of publicly traded companies continues to decline, as shown in the following chart from<a href="https://www.apolloacademy.com/significant-decline-in-the-number-of-publicly-listed-companies/" rel="noreferrer noopener" target="_blank">&nbsp;Apollo.</a>
<img alt="Number of publicly listed U.S. companies" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-59-1024x576.png" style="height:351px; width:624px" />
This decline has many reasons, including mergers and acquisitions, bankruptcy, leveraged buyouts, and private equity. For example, Twitter&nbsp;(now X)&nbsp;was once a publicly traded company before Elon Musk acquired it and took it private. Unsurprisingly, with fewer publicly traded companies, there are fewer opportunities as market capital increases. Such is particularly the case for large institutions that must deploy large amounts of capital over short periods. With nearly 40% of the companies in the Russell 2000 index currently non-profitable, the choices are limited even further.
<img alt="Percentage of companies in the Russell 2000 that are non-profitable." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-60-1024x576.png" style="height:351px; width:624px" />
However, this period&rsquo;s concentration of market capitalization into a few names is not unique. In the 1960s and 1970s, it was the&nbsp;&ldquo;Nifty 50.&rdquo; Then, in the late 90s, it was the &ldquo;Dot.com&rdquo;&nbsp;darlings like Cisco Systems. Today, it is anything related to&nbsp;&ldquo;artificial Intelligence.&rdquo;
<img alt="Stock market concentration over time. " src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-58.png" style="height:391px; width:624px" />
As shown, the leaders of the past are not today&rsquo;s leaders. Notably, Nvidia&nbsp;(NVDA)&nbsp;will get added to the list of the largest&nbsp;&ldquo;mega-cap&rdquo;&nbsp;companies for the first time in 2024.
<img alt="Stocks with the largest market capitalization over time." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-57.png" style="height:368px; width:624px" />
However, investors must decide whether Microsoft, Apple, Google, and Amazon will remain the leaders over the coming decade. Just as AT&amp;T and GM were once the darlings of Wall Street, today&rsquo;s Technology shares may become relics of the past.
<h3 id="h-earnings-growth">Earnings Growth</h3>
One primary determinant in answering that question is earnings growth. As should be obvious, investors are willing to pay higher prices when corporate earnings are growing.
<img alt="Earnings growth vs. the annual rate of change in the market." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/SP500-Earnings-vs-Ann-ROC-in-SP-500.png" style="height:332px; width:624px" />
The problem is that in 2023, all the earnings growth came from the&nbsp;index&rsquo;s top-7&nbsp;&ldquo;mega-capitalization&rdquo;&nbsp;stocks. The S&amp;P 500 would have had negative earnings growth excluding those seven stocks. Such would have likely resulted in a more disappointing market outcome. Notably, while analysts are optimistic that earnings growth for the bottom 493 stocks will accelerate into the end of 2024, with economic data slowing, those hopes will likely be disappointed.
<img alt="Earnings growth top 7 companies versus the bottom 493." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-61.png" style="height:369px; width:624px" />
Over the next decade, companies like Microsoft, Apple, and Alphabet will face the challenge of growing revenues fast enough to keep earnings growth rates elevated. Given that Nvidia is a relatively young company in a fast-growing industry, it has been able to increase revenues sharply to support higher valuation multiples.
<img alt="Nivida Revenue" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-62.png" style="height:314px; width:624px" />
However, Apple, a very mature company, cannot grow revenues at such a high rate. Such is simply because of the law of large numbers. I have included a 5-year annualized growth rate of revenues to illustrate the issue better.
<img alt="Apple Revenue" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-63.png" style="height:312px; width:624px" />
That is where the Wall Street axiom&nbsp;&ldquo;Trees don&rsquo;t grow to the sky&rdquo;&nbsp;comes from.&nbsp;&nbsp;
In investing, it describes the danger of maturing companies with a high growth rate. In some cases, a company with an exponential growth rate will achieve a high valuation based on the unrealistic expectation that growth will continue at the same pace as the company becomes larger. For example, if a company has $10 billion in revenue and a 200% growth rate, it&rsquo;s easy to think it will achieve 100s of billions in revenue within a few short years. 
However, the larger a company becomes, the more difficult it becomes to achieve a high growth rate. For example, a firm with a 1% market share might quickly achieve 2%. However, when a firm has an 80% market share, doubling sales requires growing the market or entering new markets where it isn&rsquo;t as strong. Firms also tend to become less efficient and innovative as they grow due to diseconomies of scale.
For this reason, many of today&rsquo;s top market capitalization-weighted stocks may not be the same in a decade. Just as AT&amp;T is a relic of yesterday&rsquo;s&nbsp;&ldquo;new technology,&rdquo;&nbsp;such may be true with Apple a few years from now when no one needs a&nbsp;&ldquo;smartphone&rdquo;&nbsp;anymore.
<h3 id="h-passive-investing-s-impact">Passive Investing&rsquo;s Impact</h3>
Over the last two decades, the rise of passive investing has been another interesting change in the financial markets.&nbsp;<a href="https://realinvestmentadvice.com/its-not-2000-but-there-are-similarities/" rel="noreferrer noopener" target="_blank">As discussed previously</a>, the top-10&nbsp;&ldquo;mega-capitalization&rdquo;&nbsp;stocks in the S&amp;P 500 index comprise more than 1/3rd of the index.&nbsp;In other words, a 1% gain in the top 10 stocks is the same as a 1% gain in the bottom 90%.&nbsp;As investors buy shares of a passive ETF, the ETF must purchase the shares of all the underlying companies. Given the massive inflows into ETFs over the last year and subsequent inflows into the top 10 stocks, the mirage of market stability is not surprising.
<img alt="Market cap weighting of top 10 stocks in the index" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/Top-10-Stocks-Market-Cap-Weighting-060124.png" style="height:415px; width:624px" />
Unsurprisingly, the forced feeding of dollars into the largest weighted stocks makes market performance appear more robust than it is. That is also why the S&amp;P 500 market-capitalization weighted index has outperformed the equal-weighted index over the last few years.
<img alt="Two year performance of the market-cap weighted index vs. the equal weight." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/Market-Cap-Vs-Eq-Wgt-Rel-Performance.png" style="height:350px; width:624px" />
Investors often overlook this double-edged sword. For example, let&rsquo;s assume that Tesla was 5% in the S&amp;P 500 index before Nvidia entered the top 10. As Nvida&rsquo;s rapid share price increased its market capitalization, Tesla&rsquo;s was reduced as its stock price fell. Therefore, all index funds, passive fund managers, portfolio managers, etc., had to increase their weightings in Nvidia and reduce their ownership in Tesla.
<img alt="Market capitalization of Nvidia vs Tesla." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-64-1024x421.png" style="height:257px; width:624px" />
In the future, whatever the next generation of companies garners Wall Street&rsquo;s favor, the current leaders could fall out of the top 10 as the&nbsp;&ldquo;passive&rdquo;&nbsp;flows require additional selling of today&rsquo;s leaders to buy more of tomorrow&rsquo;s.
<h3 id="h-share-buybacks">Share Buybacks</h3>
Lastly, corporate share buybacks, expected to approach $1 trillion and exceed that in 2024, could weigh on current leadership. That is because the largest companies with the cash to execute large multi-billion dollar programs, like Apple, Microsoft, Alphabet, and Nvidia, dominate buybacks. For example, Apple alone will account for over 10% of 2024 buybacks.
<img alt="Annual Share Buyback Executions" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-65.png" style="height:479px; width:624px" />
If you don&rsquo;t understand the importance of share buybacks in maintaining the largest companies&rsquo; current market dominance, here is some basic math.
<ul>
<li>Pensions and MF = (-$2.7 Trillion)</li>
<li>Households and Foreign = +$2.4 Trillion
<ul>
<li>Sub Total = (-$0.3 Trillion)</li>
</ul>
</li>
<li>Corporations (Buybacks) = $5.5 Trillion
<ul>
<li>Net Total = $5.2 Trillion</li>
</ul>
</li>
</ul>
In other words, since 2000, corporations have provided 100% of all the net equity buying.
<img alt="Net demand for U.S. Equities." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-66.png" style="height:374px; width:624px" />
Therefore, it should be unsurprising that there is a high correlation between the ebbs and flows of corporate share buybacks and market performance.
<img alt="Annual Change in buybacks vs the market" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/SP500-vs-Share-buybacks-Ann-Pct-Chg-1024x542.png" style="height:330px; width:624px" />
Therefore, as long as corporations remain the top buyers of their shares, the current dominance of the&nbsp;&ldquo;Mega-caps&rdquo;&nbsp;will continue. Of course, there are reasons the current rate of corporate share repurchases will end.
<ul>
<li>Changes to the tax code</li>
<li>A ban on share repurchases (they were previously illegal due to their ability to manipulate markets)</li>
<li>A reversal of profitability, making share repurchases onerous.</li>
<li>Economic recession/credit event where corporations go on the defensive (i.e., 2000, 2008, 2022)</li>
</ul>
Whatever the reason, the eventual reversal of buyback programs could severely limit the current leader&rsquo;s market dominance.
I have no clue what event causes such a reversal or when. However, a reversal could undo mega-cap dominance since corporate share buybacks have provided all the net equity buying for the largest stocks.
<h2 id="h-conclusion">Conclusion</h2>
The current dominance of the largest &ldquo;Mega-capitalization&rdquo;&nbsp;companies is unsurprising. As noted, they make up the bulk of earnings growth and revenues of the S&amp;P 500 index, the largest purchasers of their shares. These are also the same companies in the middle of the current &ldquo;Artificial Intelligence&rdquo; revolution, as has been the case for the last decade.
However, given the speed at which technology and the economy rapidly change, such suggests that leaders of the last decade may not be the leaders of the next.
<img alt="Historical Market Bubbles" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-67.png" style="height:363px; width:624px" />
As investors, it is vital to understand the dynamics of each market cycle and invest accordingly. However, those buying stocks today at some of the most extreme valuations we have seen over the last century and expecting those shares to dominate over the next decade could be disappointed.
Many variables support the current secular bull market cycle. However, as has been the case throughout history, a myopic approach to investing has led to poor outcomes.
Invest accordingly.
Lance Roberts is a Chief Portfolio Strategist/Economist for&nbsp;<a href="https://realinvestmentadvice.com/investing/" target="_blank">RIA Advisors</a>. He is also the host of &ldquo;<a href="https://realinvestmentadvice.com/podcasts/" target="_blank">The Lance Roberts Podcast</a>&rdquo; and Chief Editor of the &ldquo;<a href="https://realinvestmentadvice.com/" target="_blank">Real Investment Advice</a>&rdquo; website and author of &ldquo;<a href="https://realinvestmentadvice.com/real-investment-daily/" target="_blank">Real Investment Daily</a>&rdquo; blog and &ldquo;Real Investment Report&ldquo;. Follow Lance on&nbsp;<a href="https://www.facebook.com/RealInvestmentAdvice/" target="_blank">Facebook</a>,&nbsp;<a href="https://twitter.com/LanceRoberts" target="_blank">Twitter</a>,&nbsp;<a href="https://www.linkedin.com/in/realinvestmentadvice/" target="_blank">Linked-In</a>&nbsp;and&nbsp;<a href="https://www.youtube.com/channel/UCXVMMgEidXlrTM1coedg70A" target="_blank">YouTube</a>

Can Mega-Capitalization Stocks Continue Their Dominance?

Monday, Addex Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), has discontinued the development of ADX71149 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39875937/addexs-partner-discontinues-adx71149-development-in-epilepsy" rel="noreferrer noopener">(JNJ-40411813) in epilepsy</a>.
The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 (JNJ-40411813) as an adjunctive epilepsy treatment is analyzed.
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38493033/johnson-johnson-partnered-addex-therapeutics-epilepsy-candidate-fails-mid-stage-study-stock-tanks" rel="noreferrer noopener">added to standard of care</a>.
After the data, Addex Therapeutics stock tumbled almost 50%.
&#8220;Following the Phase 2 study results in epilepsy, this decision was anticipated. We have had an excellent working relationship with Janssen for twenty years and will continue to work diligently to complete the analysis of the full Phase 2 data set to elucidate all learnings from the study,&#8221; said Tim Dyer, CEO of Addex. &#8220;Once we have that information in hand, we anticipate a decision on the future of this asset.&#8221;
Price Action: ADXN stock is down 1.36% at $7.99 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39864734/craze-for-ozempic-and-zepbound-for-weight-loss-leave-diabetic-patients-without-critical-glp-1-med" target="_blank" rel="noreferrer noopener">Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications</a>.</li>
</ul>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Estrella Immunopharma

News

Latest news for Estrella Immunopharma (NASDAQ:ESLAW) Stock

People Also Watch